Cargando…
New insights into acquired endocrine resistance of breast cancer
The translational research strategy of targeting estrogen receptor α (ERα) positive breast cancer and then using long term anti-hormone adjuvant therapy (5-10 years) has reduced recurrences and mortality. However, resistance continues to occur and improvements are required to build on the success of...
Autores principales: | Fan, Ping, Jordan, V. Craig |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OAE Publishing Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6897388/ https://www.ncbi.nlm.nih.gov/pubmed/31815253 http://dx.doi.org/10.20517/cdr.2019.13 |
Ejemplares similares
-
PERK, Beyond an Unfolded Protein Response Sensor in Estrogen-Induced Apoptosis in Endocrine-Resistant Breast Cancer
por: Fan, Ping, et al.
Publicado: (2022) -
Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer
por: Nicholson, RI, et al.
Publicado: (2000) -
Exploring new pathways in endocrine-resistant breast cancer
por: de Pinho, Inês Soares, et al.
Publicado: (2022) -
A quiet revolution in the endocrine therapy of breast cancer
por: Craig Jordan, V
Publicado: (2003) -
Statins and endocrine resistance in breast cancer
por: Hyder, Tara, et al.
Publicado: (2021)